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ABSTRACT
Ovarian cancer is the most lethal gynecologic disease because usually, it is 
lately sensed, easily acquires chemoresistance, and has a high recurrence rate. 
Recent studies suggest that ovarian cancer stem cells (CSCs) are involved in these 
malignancies. Here, we demonstrated that galectin-3 maintains ovarian CSCs by 
activating the Notch1 intracellular domain (NICD1). The number and size of ovarian 
CSCs decreased in the absence of galectin-3, and overexpression of galectin-3 
increased them. Overexpression of galectin-3 increased the resistance for cisplatin 
and paclitaxel-induced cell death. Silencing of galectin-3 decreased the migration 
and invasion of ovarian cancer cells, and overexpression of galectin-3 reversed 
these effects. The Notch signaling pathway was strongly activated by galectin-3 
overexpression in A2780 cells. Silencing of galectin-3 reduced the levels of cleaved 
NICD1 and expression of the Notch target genes, Hes1 and Hey1. Overexpression 
of galectin-3 induced NICD1 cleavage and increased expression of Hes1 and Hey1. 
Moreover, overexpression of galectin-3 increased the nuclear translocation of NICD1. 
Interestingly, the carbohydrate recognition domain of galectin-3 interacted with 
NICD1. Overexpression of galectin-3 increased tumor burden in A2780 ovarian cancer 
xenografted mice. Increased expression of galectin-3 was detected in advanced 
stages, compared to stage 1 or 2 in ovarian cancer patients, suggesting that galectin-3 
supports stemness of these cells. Based on these results, we suggest that targeting 
galectin-3 may be a potent approach for improving ovarian cancer therapy.
INTRODUCTION
Ovarian cancer, the fifth leading cause of cancer-
related death in women, is the most lethal disease among 
all gynecologic malignancies [1]. Ovarian cancer is 
a heterogeneous disease; however, epithelial ovarian 
carcinoma (EOC) is the major form of the disease and 
accounts for approximately 90% of ovarian tumors [2]. 
Subtypes of epithelial ovarian cancers can be divided into 
two groups: type I and type II [3]. Type 1 tumors are low-
grade, slow growing, generally confined to the ovary at 
diagnosis, and develop from well-established precursor 
lesions; whereas, type 2 tumors are high-grade and rapidly 
progressing, for which well-defined precursor lesions have 
not been described [4]. Moreover, gene expression studies 
have shown that high-grade tumors cluster separately from 
low-grade and borderline tumors, suggesting that the two 
groups of tumors have a different genetic makeup [5, 6]. 
These data underscore the need for studies that probe the 
underlying molecular mechanism of ovarian cancer.
The combination of surgery and platinum-based 
chemotherapy was the standard treatment for advanced 
ovarian cancer [1]. Although a deeper understanding 
of disease progression has led to the development of 
numerous molecular targeting agents, recurrence still 
commonly occurs within 18 months of first line treatment 
in 70% of patients. The five-year survival rate of patients 
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with advanced ovarian cancer is only 30.6% [7]. Recently, 
scientists have proposed that the cancer stem cells (CSCs) 
or cancer-initiating cells (CICs) are one of the reasons 
for disease relapse [4]. Traditional chemotherapy can kill 
the majority of cancer cells, while failing to target CSCs. 
Because CSCs has the properties as like normal stem cells, 
which are more resistant to DNA damage induced cell death 
than their more committed progeny, leading to a short-
term survival advantage at the expense of the long-term 
maintenance of their genomic integrity [8]. It suggests that 
initial treatment increased the proportion of drug-resistant 
CSCs, resulting in recurrence of disease. Therefore, defining 
ovarian CSCs and identifying the regulatory molecules are a 
critical therapeutic approach for effective treatment. 
Galectin-3 is a β-galactose-containing glycoconjugate-
binding lectin. The amino acid sequence of galectin-3 
contains a C-terminal carbohydrate recognition domain 
(CRD) that binds to β-galactosides, and an N-terminal 
domain with critical multivalent behavior [9]. The function 
of galectin-3 as an extracellular protein is well known, 
because of its ability to cross-link and cluster integrins; 
however, intracellular galectin-3 also functions as regulator 
of cellular processes [10]. Moreover, studies suggest 
galectin-3 regulates cancer progression, including cell 
proliferation, apoptosis, migration, and invasion [11–13]. 
In ovarian cancer, galectin-3 increases drug resistance and 
is also associated with poor survival rates in ovarian cancer 
patients [14–16]. These data strongly suggest that galectin-3 
regulates stemness of ovarian cancer cells; however, 
additional studies are needed to elucidate the molecular 
mechanisms and phenotypes of cancer stem cells. 
In this study, we determined the molecular 
mechanism by which galectin-3 increases the proliferation 
of ovarian cancer cells in vivo and in vitro. Moreover, we 
determined a role for galectin-3 in the maintenance of 
ovarian CSCs. Our results suggest that galectin-3 may be 
a potent target for ovarian cancer therapy.
RESULTS
Galectin-3 regulates cancersphere formation, 
which is a stem cell like-phenotype, during 
cultivation of ovarian cancer cells
We monitored galectin-3 expression in ten different 
ovarian cancer cell lines using RT-PCR and western blot 
analysis (Supplementary Figure S1A). We also determined 
the ability of cancersphere formation in ten ovarian 
cancer cells (Supplementary Figure 2). Among of them, 
A2780, OVCAR3, OVCAR429, SNU-251 and SKOV3 
showed high ability for cancersphere formation. From 
these experiments, we selected A2780 and OVCAR3, 
as galectin-3 low-expressing cells, and SKOV3 and 
OVCAR429, as galectin-3 high-expressing cells, for 
further study.
To determine the effect of galectin-3 on the sphere 
formation of ovarian cancer cells, we prepared galectin-
3-depleted cells by treating galectin-3 specific shRNA in 
galectin-3 high-expressing SKOV3 and OVCAR429 cells 
(Supplementary Figure S1B). After cultivation in sphere 
forming culture media, the sphere size and the number 
of spheres were both smaller in galectin-3 depleted cells 
than in control cells (Figure 1A) Total number of cells 
to form cancer sphere were also lower than control cells 
(Figure 1B and Supplementary Figure S3A).
We also prepared galectin-3-overexpressed cells by 
transforming PLL3.7-galectin-3 containing plasmids into 
the galectin-3 low-expressed A2780 and OVCAR3 cells 
(Supplementary Figure S1C). The sphere size and the 
number of spheres were larger for galectin-3-overexpresed 
cells than for the control cells (Figure 1C). Total number 
of cells to form cancer sphere were also more than control 
cells (Figure 1D and Supplementary Figure S3B).
The expression of the stem cell marker, CD133, also 
significantly increased in galectin-3-overexpressed A2780 
cells (Figure 1E). Moreover, both CD133 and galectin-3 
expression was increased after sphere forming cultivation of 
OVCAR3 cells (Figure 1F). These data suggest that galectin-3 
increases cancer stem cell property in ovarian cancer cells.
Galectin-3 regulates cell proliferation and 
chemotherapeutic agents-induced cell death in 
ovarian cancer cells
Depletion of galectin-3 induced the cell proliferation 
in SKOV3 and OVCAR429 cells (Figure 2A) and 
overexpression of galectin-3 increased the cell proliferation 
in A2780 and OVCAR3 cells (Figure 2B). Interestingly, 
overexpression of galectin-3 significantly inhibited the 
cisplatin and paclitaxel-induced cell death of A2780 cells 
(Figure 2C) and OVCAR3 cells (Figure 2D). Moreover, 
depletion of galectin-3 enhanced paclitaxel-induced 
apoptosis in SKOV3 cells (Supplementary Figure S4A) and 
overexpression of galectin-3 reduced paclitaxel-induced 
apoptosis in A2780 cells (Supplementary Figure S4B). 
These data supposed that galectin-3 is involved in drug 
resistance, which is a phenotype of cancer stem cells, to 
protect the chemotherapeutic agents induced cell death.
Galectin-3 regulates the invasion and migration 
of ovarian cancer cells
We prepared galectin-3-depleted cells by treating 
SKOV3 cells and OVCAR429 cells with galectin-3 
specific siRNA (Figure 3A), and performed wound 
healing (Figure 3B), invasion (Figure 3C), and migration 
(Figure 3D) assays. The motility of galectin-3-depleted 
SKOV3 cells and OVCAR429 cells was significantly 
reduced in these assays. We also prepared galectin-3-
overexpressed A2780 and OVCAR3 cells (Figure 3E) 
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and performed wound healing (Figure 3F), invasion 
(Figure 3G), and migration (Figure 3H) assays. 
Overexpression of galectin-3 increased the motility of 
A2780 and OVCAR3 ovarian cancer cells. These results 
suggested that galectin-3 promotes the cell invasion and 
migration in ovarian cancer cells.
Overexpression of galectin-3 increases the 
expression of genes involved in stemness 
regulating signaling pathways
We determined the regulators of stemness 
phenotype, such as EMT regulators and stemness factors 
in absence of galectin-3 in SKOV3 and OVCAR429 
cells (Figure 4A) and in overexpression of galectin-3 in 
A2780 and OVCAR3 cells (Figure 4B). After depletion 
of galectin-3, EMT regulators such as TWIST and SNAIL 
were slightly decreased and ZEB1 was significantly 
decreased in both SKOV3 and OVCAR429 cells. 
Stemness factors, such as NANOG, OCT4 and SOX2 
were drastically decreased in galectin-3-depleted SKOV3 
and OVCAR429 cells (Figure 4A). Moreover, we 
detected that EMT regulators, TWIST, SNAIL and ZEB1 
were slightly increased and NANOG, OCT4 and SOX2, 
stemness factors were drastically increased in galectin-3-
overexpressed A2780 and OVCAR3 cells (Figure 4B). 
To determine how galectin-3 could regulate the 
stemness phenotype of ovarian cancer cells, we measured 
the mRNA expression of Notch, WNT/β-catenin, and 
SHH signaling pathway related genes in galectin-3-
Figure 1: Galectin-3 regulates cancersphere formation, which is a stem cell like phenotype, in ovarian cancer cells. 
(A and B) Detection of ovarian cancerspheres prepared by galectin-3-depleted SKOV3 and OVCRA429 cells or (C and D) galectin-3-
overexpressed A2780 and OVCAR3 cells. (A and C) Galectin-3 shRNA containing lentiviruses (A) or galectin-3 overexpression vector 
containing lentiviruses (C) were infected in cells and stable galectin-3-depleted cells were selected by puromucin. These cells were cultured 
for 14 days and the morphology was taken by photographes. Scale bar represents 50 μm. (B and D) Galectin-3-depleted ovarian cancerspheres 
(B) or galectin-3-overexpressed (D) ovarian cancer spheres were collected and separated into single cells by trypsin treatment. The sphere 
forming cell numbers were calculated and prepared graphs by ratio of total seeded cell numbers. (E) Detection of CD133 expression level in 
galectin-3 overexpressed A2780 cells. The expression level was detected by real-time PCR analysis. (F) Detection of galectin-3 and CD133 
expression level in OVCAR3 ovarian cancer spheres formed cells. The data are presented as the mean ± SD (n = 3). Significant differences 
are indicated by an asterisk (*p < 0.05), and the p values were calculated using the Student’s t test. 
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depleted SKOV3 cells (Figure 4C). These signaling 
pathways were previously reported to be involved in 
maintaining cancer stem cells. Interestingly, depletion of 
galectin-3 reduced the expression of most target genes 
for these pathways. Among them, the expression of the 
Notch target genes such as Hes1 and hey1 were strongly 
decreased by depletion of galectin-3 (Figure 4C). We also 
analyzed the mRNA expression levels of these genes in in 
galectin-3-overexpressing A2780 cells (Figure 4D). The 
expression of HES1 and HEY1 was significantly increased 
by galectin-3 overexpression. These results suggested that 
galectin-3 significantly regulates stemness factors through 
Notch signaling pathway in ovarian cancer cells.
Galectin-3 induces cleavage and nuclear 
translocalization of Notch1 intracellular domain 
(NICD1) and the expression of the Notch target 
genes, such as HES1 and HEY1
We next determined how galectin-3 regulates Notch 
signaling in ovarian cancer cells. After silencing galectin-3 
with two different galectin-3 specific siRNAs in SKOV3 
cells, Notch1 expression did not change; however, levels 
of the cleaved form of the Notch1 intracellular domain 
(NICD1) decreased (Figure 5A). Silencing galectin-3 
significantly reduced the levels of nuclear localized NICD1 
(Figure 5B), and the expression levels of the Notch1 target 
genes, HES1 and HEY1 in SKOV3 cells (Figure 5C). Not 
only in SKOV3 cells, we also determined the effect of 
galectin-3 on NICD1 formation in SNU-840, DOV13 and 
RMUG-1 ovarian cancer cells (Supplementary Figure 5). 
Depletion of galectin-3 reduced the expression of cleaved 
NICD1 in these cells. 
Galectin-3 overexpression did not affect the 
expression of the Notch1 genes, but induced the cleaved 
form of NICD1 (Figure 5D). We detected increased levels 
of NICD1 in nuclear fractions of galectin-3 overexpressing 
cells by western blot (Figure 5E). The expression of Hes1 
and Hey1 also increased in galectin-3-overexpressing 
A2780 ovarian cancer cells (Figure 5F). Interestingly, we 
detected the colocalization of galectin-3 and NICD1 in 
nucleus of SKOV3 cells, whereas depletion of galectin-3 
diminished their expression in nucleus (Figure 5G). 
Overexpression of galectin-3 induced accumulation of 
NICD1 in nucleus and colocalization of galectin-3 and 
NICD1 in A2780 cells (Figure 5G).
Figure 2: Galectin-3 regulates cell proliferation and drug resistance in ovarian cancer cells. (A and B) (A) galectin-3 
shRNA was transfected in SKOV3 cells and OVCAR429 cells, and (B) galectin-3 overexpression vector was transfected in A2780 cells 
and OVCAR3 cells. LacZ shRNA and PLL3.7 mock vector were used as the transfection control. Cell viability was analyzed by WST 
assays. (C and D) galectin-3 overexpression vector was transfected in A2780 cells and OVCAR3 cells. pLECE mock vector was used as 
a transfection control. After chemotherapeutic drugs, indicated paclitaxel, cisplatin, treatment for 48 hrs, cell viability was measured by 
WST assay. The data are presented as the mean ± SD (n = 3). Significant differences are indicated by an asterisk (*p < 0.05). The p values 
were calculated using the Student’s t test.
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Interestingly, silencing of Notch1 with two different 
Notch1 specific siRNAs did not effect on the expression 
level or nuclear localization of galectin-3 in SKOV3 
cells (Supplementary Figure S6A and S6B), and NCID1 
overexpression did not induce the galectin-3 expression 
in A2780 cells (Supplementary Figure 6C). These data 
strongly suggest that overexpression of galectin-3 
increases the cleavage and the nuclear translocalization of 
NICD1 in ovarian cancer cells.
The CRD domain of Galectin-3 directly interacts 
with NICD1 
We tested the ability of galectin-3 to interact 
with Notch1 using an immunoprecipitation assay (IP) 
(Figure 6A). We detected interaction between galectin-3 
and Notch1 in reciprocal IP assays using antibodies 
against galectin-3 and Notch 1, which suggests that 
galectin-3 directly interacts with Notch1. We then 
Figure 3: Galectin-3 regulates invasion and migration of ovarian cancer cells. (A–D) SKOV3 cells and OVCAR429 were 
transfected with galectin-3 siRNA. Scrambled RNA (scRNA) was used as a transfection control. (A) Detection of galectin-3 protein 
expression by western blot analysis, (B) Detection of the healing ability by wound healing assays, (C) Invasion activity and (D) migration 
assay by trans-filter well assays. (E–H) A2780 and OVCAR3 cells was transfection with flag-tagged galectin-3 expression vector. pcDNA3.0 
mock vector was used as a transfection control. (E) Detection of galectin-3 protein expression by western blot analysis, (F) Detection of 
the healing ability by wound healing assays, (G) Invasion activity and (H) migration assay by trans-filter well assays. Data are presented 
as mean ± SD (n = 3). The significant differences are indicated by asterisk (*p < 0.05), p values were calculated using the Student’s t tests.
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performed the IP assay using antibodies against cleaved 
NICD1 and galectin-3 (Figure 6B). These data suggested 
that galectin-3 interacted with the intracellular domain of 
Notch1. 
Moreover, we prepared plasmids containing the 
galectin-3 peptide domain (Figure 6C). These plasmids 
were trasfected in A2780 cells. After performing IP assay 
using FLAG antibodies, we found that NICD1 interacted 
with amino acids 111–250, which is the carbohydrate 
recognition domain of galectin-3 (Figure 6D). 
Overexpression of galectin-3 increases the tumor 
growth in ovarian cancer cells xenografted mice
We performed xenograft assays using galectin-3-
overexpressing A2780 cells on nude mice (Figure 7A 
and 7B). The size of tumors prepared by galectin-3 
overexpressing A2780 cells was larger than that of control 
A2780 cells. The growth rate of galectin-3 overexpressing 
A2780 cells were also faster than those of parent cells 
(Figure 7A). We determined the expression level of NICD1 
and stemness factors, such as NANOG, OCT4 and SOX-2 
in tumor sections prepared galectin-3 overexpressing 
A2780 cells (Figure 7B). Compared to tumor sections 
prepared by control A2780 cells, the expression of 
NICD1, NANOG, OCT4 and SOX2 was significantly 
increased in those prepared by galectin-3 overexpressing 
A2780 cells.
Expression of galectin-3 is higher in malignant 
tissues of stage 4 ovarian cancer patients than in 
those of stage 2 ovarian cancer patients
We analyzed the expression level of galectin-3 in 
malignant tissues of ovarian cancer patients using TCGA 
public database (Figure 7C). The expression is increased 
according to stages; the expression of galectin-3 is 
higher in stage 4 than in stage 1. It strongly supports that 
galectin-3 promotes the malignancy of ovarian cancer.
Figure 4: Galectin-3 regulates the Notch signaling and cancer stemness factors. (A and B) Stemness and dedifferentiation 
related proteins were detected by western blot analysis in (A) galectin-3 siRNA transfected SKOV3 cells and OVCAR429 cells and (B) 
galectin-3 overexpressing vector transfected A2780 cells and OVCAR3 cells. Scrambled RNA (scRNA) and pcDNA3.0 mock vector 
were used as the transfection control, respectively. GAPDH was used as a loading control for western blot analysis. (C and D) (C) RT and 
real-time PCR analysis of CD133, HEY1, HES1, CCND1, C-MYC, TCF, GLI1, GLI3, and LGALS3 abundance in scRNA or galectin-3 
siRNA transfected SKOV3 cells. (D) Real-time PCR analysis of CD133, HEY1, HES1, CCND1, C-MYC, TCF, GLI1, GLI3, and LGALS3 
abundance in galectin-3-overexpressing vector transfected A2780 cells. Scrambled RNA (scRNA) and pcDNA3.0 mock vector were used 
as the transfection control, respectively. The expression level of GAPDH was analyzed for normalization control.
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DISCUSSION
Cancer stem cells (CSCs), or cancer-initiating cells 
(CICs), have been increasingly studied over the past 
decade as a malignant and aggressive cancer phenotype. 
Although the origin of these cells is not fully understood, 
tumor heterogeneity, and the small populations of cells 
with stem-like characteristics, have been identified in 
many malignancies and are hypothesized to form the 
clonogenic core of tumor tissues [17, 18]. Such cells 
potentially originate from a more-differentiated cancer 
cell that acquires self-renewal properties, and the ability to 
undergo the epithelial-to-mesenchymal transition (EMT) 
[19]. Despite recent findings, the CSC hypothesis remains 
controversial. This controversy arises as a consequence 
of the technical and logistical challenges in isolating and 
identifying CSCs from human solid tumors that contain 
heterogeneous cell populations, and the limited number 
of validated surrogate assays currently available to 
substantively confirm stem-cell-like properties. However, 
surrogate assays for CSCs have been established that 
involve the formation of secondary ‘spheroids’ in 
suspension culture and the generation of 3D organoids [20]. 
Therefore, we examined the major properties of 
CSCs, spheroids formation and cell motility, which are the 
result of EMT. After depletion of galectin-3 expression, 
we performed suspension cultures for spheroids formation 
and drug sensitivity, and invasion and migration assays. 
Figure 5: Galectin-3 induces the cleavage and nuclear translocation of Notch1 intracellular domain (NICD1) and the 
expression of the Notch target genes HES1 and HEY1. (A) Detection of mRNA and protein expression of galectin-3, Notch1 and 
NICD1 in galectin-3 silenced SKOV3 cells by RT-PCR and immunoblotting, respectively. β-actin was used as a loading control. (B) Protein 
levels of NICD1 and galectin-3 were detected in the nuclear and cytosol fractions of SKOV3 cells that were transfected with scRNA or 
galectin-3 siRNA. GAPDH and Lamin A/C were used as loading controls. (C) Protein levels of galectin-3, NICD1, HES1, and HEY1 in 
SKOV3 cells transfected with scRNA or galectin-3 siRNA. GAPDH was used as a loading control. (D) Detection of mRNA and protein 
expression of galectin-3, Notch1 and NICD1 in A2780 cells transfected with control vector or with the galectin-3 expression vector by RT-
PCR and immunoblotting, respectively. β-actin was used as a loading control. (E) Protein levels of NICD1 and galectin-3 were detected in 
the nuclear and cytosol fractions of A2780 cells that were transfected with control or galectin-3 expression vector. GAPDH and Lamin A/C 
were used as loading controls. (F) Protein levels of galectin-3, NICD1, HES1, and HEY1 in A2780 cells transfected with mock vector or 
galectin-3 overexpressing vector. GAPDH was used as a loading control. (G) Immunocytochemical analysis was performed for detection 
of co-localization NICD1 and galectin-3 after transfection with scRNA or galectin-3 siRNA in SKOV3 cells (upper) and transfection with 
mock vector or galectin-3 expression vector (lower) in A2780 cells. Scale bar represents 50 μm. DAPI staining was used for detection of 
nucleus and the procedure was described in “Materials and Methods”.
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Interestingly, depletion of galectin-3 significantly 
reduced spheroid formation, drug resistance and ovarian 
cancer cell motility. These results strongly suggested 
that galectin-3 increases the stem-like characteristics 
of ovarian cancer cells. Previously, it was reported that 
EGFR-dependent SOX2 expression or β-catenin activation 
by galectin-3 regulates lung cancer stem cells [21, 22]. 
We also reported that galectin-3 interacts with GSK-3b 
and then regulates WNT signaling to promote gastric 
cancer motility [9]. To identify the signaling pathways 
that are involved in galectin-3 dependent regulation of 
ovarian CSCs, we performed the depletion of galectin-3 
in SKOV3 and overexpression of galectin-3 in A2780 
cells and determined the signaling pathway related in CSC 
maintenance. CSCs display many features of embryonic 
or tissue stem cells, and typically demonstrate persistent 
activation of one or more highly conserved signal 
transduction pathways involved in development and tissue 
homeostasis, including the Notch, Hedgehog (HH), and 
WNT pathways [19]. Interestingly, we determined that 
Notch signaling related genes were drastically changed by 
galectin-3 expression. Depletion of galectin-3 significantly 
reduced the expression of HEY1 and HES1 in SKOV3 
cells and overexpression of galectin-3 significantly 
increased their expression in A2780 cells, compared 
to target genes of the Hedgehog and WNT signaling 
pathways. Of course, overexpression of galectin-3 also 
increased target genes of Hedgehog and WNT signaling 
pathways, suggested that galectin-3 promotes ovarian 
CSCs by harmonized these signaling pathways, also. 
We are now studying how galectin-3 harmonized these 
signaling pathways.
We were interested that galectin-3 regulates 
the Notch1 signaling pathway in ovarian cancer 
stem cells because Notch pathway genes might be 
important therapeutic targets for CSCs and many new 
agents targeting the Notch pathways have entered 
clinical trials [23]. The Notch signaling pathway is an 
evolutionarily conserved pathway that plays an important 
role in development and cell fate determination, from 
angiogenesis to microenvironmental development, and 
immune response [23]. Notch is a large transmembrane 
protein that contains an EGF-like extracellular domain that 
is involved in ligand binding, a transmembrane domain, 
and an intracellular, nuclear localization domain. Ligand 
binding initiates cleavage of the intercellular domain, 
Figure 6: Galectin-3 interacts with NOTCH1 and NICD1 through its C-terminal domain. (A and B) Immunoprecipitation 
was performed using (A) antibodies against galectin-3 and Notch1 or (B) antibodies against galectin-3 and NICD1 to detect interactions 
between galectin-3 and NICD1 in the SKOV3 cells. (C) Schematic model of Flag-galectin-3 domain (full length: amino acids 1–250, and 
CRD truncations: amino acids 33–250, 63–250, and 111–250). (D) Immunoprecipitation of Flag-galectin-3 domains and NICD1 using 
transfection of the galectin-3 domains in A2780 cells. β-actin was used as the loading control.
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by the enzyme g-secretase. The cleaved domain, NCID, 
then translocates to the nucleus where it binds to the 
transcriptional complex, CBF-1 [24]. Previously, it was 
reported that OVCAR3, SKOV3, and CaOV3 cells, as 
well as a large portion (76%) of human ovarian papillary 
serous adenocarcinomas, express NICD, which is a 
potential target for new drug therapies in ovarian cancer 
[25]. Notch signaling is also a potential diagnostic marker 
of epithelial ovarian cancer [26]. Up-regulation of the 
Notch3 and increased expression of the Jagged2 was 
reported in ovarian cancers [27, 28]. Studies of the role 
of Notch1 in ovarian cancer indicated that mRNAs of the 
Notch pathway genes were highly expressed in ovarian 
adenocarcinomas, borderline tumors, and adenomas, and 
NCID1 overexpression increased cell proliferation and 
colony-formation capacity [29]. Sphere forming primary 
serous ovarian cancer cells also show increased resistance 
to cisplatin and paclitaxel [30]. These spheroid ovarian 
CSCs showed elevated levels of the CSC marker proteins 
CD44 and CD117, as well as increased Notch1 mRNA 
levels when compared to parental bulk tumor cells [31]. 
These previous reports suggest that cleaved NICD1 
enhances stemness of ovarian CSCs. Here, we strongly 
suggest that galectin-3 is highly expressed and induces the 
cleavage and nuclear translocation of NICD1 in ovarian 
CSCs, which is an important regulatory mechanism 
of ovarian CSCs. Moreover, it is interesting that the 
carbohydrate-recognition domain (CRD) of galectin-3 
interacted directly with NICD1. There are several 
hypotheses of why or how the galectin-3 CRD binds to 
NICD1 [32], and one possibility is that the galectin-3 CRD 
recognizes post-translationally glycosylated NICD1. We 
are currently testing this hypothesis with galectin-3. 
Taken together, we conclude from this study 
that galectin-3 interacts with NICD1 and increases its 
cleavage and nuclear localization to support ovarian 
cancer stemness. Moreover, regulatory molecules for the 
Notch pathway may be critical therapeutic targets for 
blocking CSC self‑renewal and proliferation, and tumor 
progression. Therefore, we strongly suggest that galectin-3 
may be a potent target for regulating Notch1 signaling in 
ovarian cancer therapeutic strategies. 
Figure 7: Overexpression of galectin-3 increases the tumor growth in xenografted mouse tumors. A2780cells were 
transfected galectin-3 overexpression vectors and these cells were performed subcutaneous inoculation in nude mice. (A) Tumor formation 
was quantified by measuring the tumor volume 15 days after inoculation and represent as a graph (n = 3., left panel). The error bars indicate 
95% confidence intervals; *p < 0.05 using two sided t-test. All statistical tests were two sided. Tumor formation was observed 41 days after 
inoculation and taken by photpgraphs (right panel) (B) Immunohistochemistry (IHC) analysis was performed to detect the expression level 
of galectin-3, NICD1, NANOG, OCT4, and SOX2 in tumors in in vivo mouse models. Method of IHC analysis was described in “Materials 
and Methods”. Scale bar presents 200 μm. (C) The expression level of galectin-3 was analyzed by stages in malignant tissues of ovarian 
cancer patients from TCGA database. The analysis method was described in “Materials and methods”. 
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MATERIALS AND METHODS
Cell culture
The human ovarian cancer cell lines, A2780, 
DOV13, OVCAR3, OVCAR429, RMUG-I, RMUG-S, 
SKOV3, SNU-251, SNU-840, and TOV112D, were 
obtained from the Korea Cell Line Bank (KCLB, Seoul, 
Korea) and maintained in RPMI 1640, Ham’s F-12 and 
Dulbecco’s Modified Eagle Medium (DMEM) with 10% 
fetal bovine serum (FBS : Corning Costar, USA) and 1% 
antibiotics (Gibco, USA). Cells were cultured at 37°C in 
an atmosphere of 5% CO2.
Mammosphere culture
Cells were grown in ultra-low attachment plates 
(Corning) and in Mammary Epithelium Basal Medium 
(MEBM; Lonza) supplemented with B27 (Gibco), 20 
ng/mL of epidermal growth factor (EGF), and 20 ng/mL 
of fibroblast growth factor-basic (bFGF, PeproTech) 
at a density of 3,000 cells/mL as previously described 
[33]. After culturing the cells for 14 days, we counted 
mammospheres with diameters > 50 μm.
Lentiviral vector construction
Lentiviral vectors for overexpression of galectin-3 
were constructed by inserting the galectin-3 gene into 
the lentiviral vector pLL3.7 and pLECE3, as described 
previously [34]. Galectin-3 small hairpin RNA (shRNA)-
lentiviral vectors were purchased from Sigma-Aldrich. 
Galectin-3 shRNA lentiviruses were prepared as described 
previously [35].
siRNA transfection, Galectin-3 and NICD over-
expression
Transfection with galectin-3, NICD expression 
vectors, as well as with galectin-3 and Notch1 
siRNA, was performed using Lipofectamine 2000 and 
Lipofectamine RNAiMAX (Invitrogen), according to 
the manufacturer’s instruction. Galectin-3 siRNA#1 
(5′-AUAUGAAGCACUGGUGAGGUCUAUG-3′), galec 
tin-3 siRNA#2 (5′-GAAGAAAGACAGUCGGUUU-3′) 
and Notch1 siRNA#1 (5′-UCGCAUUGACCAUUCAAAC 
UGGUGGUU-3′), Notch1 siRNA#2 (5′-CGCUGCCUGG 
ACAAGAUCAAUU-3′) were purchased from Genolution 
(korea). 
Transwell migration and invasion assays 
OVCAR429 and SKOV3 cells were transfected with 
scRNA and galectin-3 siRNA. A2780 and OVCAR3 were 
transfected with a control vector and galectin-3 expression 
vector. After transfection for 24 hrs, cells (A2780 
– 1 × 104, OVCAR3 – 1 × 104, OVCAR429 – 1 × 104, 
SKOV3 – 1 × 104 in each well) were isolated and added to 
the upper Transwell (Corning Costar, USA) chambers with 
0.5 mg/mL collagen type I (BD Bioscience, Korea)-coated 
filters for the migration assay, and with a 1/14 dilution 
of Matrigel (BD Bioscience, Korea)-coated filters for the 
invasion assays. RPMI 1640 (A2780, OVCAR3, SKOV3) 
or DMEM (OVCAR429) containing 10% FBS and 1% 
antibiotics was added to the lower chamber and incubation 
was continued for 24 hrs. Cells that migrated or invaded 
the lower chamber were quantified after H&E staining, as 
previously described [36]. For quantification, cells were 
counted in four randomly selected areas in each well using 
wide-field microscopy. Graphs were expressed as mean ± 
SD from three independent experiments.
Total RNA isolation and reverse transcriptase 
polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRIzol Reagent 
(Invitrogen) according to the manufacturer’s instructions. 
Subsequently, RT-PCR, using the Reverse Transcription 
System (Promega, Madison, WI, USA), was performed 
as previously described [12]. The following primers 
were used: Lgals3, forward 5′-ATGGCAGACAATTT 
TTCGCTCC-3′ and reverse 5′-ATGTCACCAGAAATTCC 
CAGTT-3′; β-actin, forward 5′-AGCCTCGCCTTTGC 
CGA-3′ and reverse 5′-CTGGTGCCTGGGGCG-3′; 
Notch1, forward 5′- GAGGCGTGGCAGACTATGC-3′ 
and reverse 5′-CTTGTACTCCGTCAGCGTGA-3′; and 
GAPDH, forward 5′-GGCTGCTTTTAACTCTGGTA-3′ 
and reverse 5′-ACTTGATTTTGGAGGGATCT-3′. PCR 
was performed using Ex-Taq (TaKaRa, Shiga, Japan) 
according to the manufacturer’s instructions [37].
Quantitative RT–PCR
Total tissue RNA was prepared using TRIzol reagent 
(Invitrogen) according to the manufacturer’s instructions. 
cDNA (3 μg) was synthesized from RNA using the 
Quantitative RT-PCR Master Mix (TOYOBO). The 
following primers were used: GLI1, forward 5′-TGGAT 
ATGATGGTTGGCAAGTG-3′ and reverse 5′-ACAGAC 
TCAGGCTCAGGCTTCT-3′; GLI3 forward 5′-GAAGTG 
CTCCACTCGAACAGA-3′ and reverse 5′-GTGGCTG 
CATAGTGATTGCG-3′; TCF1, forward 5′-CACGGGCA 
AACACTACGGT-3′ and reverse 5′-TTGACCTTCGAGT 
GCTGATCC-3′; C-MYC, forward 5′-TTCGGGTAGTGG 
AAAACCAG -3′ and reverse 5′-CAGCAGCTCGAATTTC 
TTCC -3′; CCND1, forward 5′-AACTACCTGGACCGC 
TTCCT-3′ and reverse 5′-CCACTTGAGCTTGTTCAC 
CA-3′; HES1, forward 5′-ATGGAGAAAAATTCCTCGTC 
CC-3′ and reverse 5′-TTCAGAGCATCCAAAATCAG 
TGT-3′; HEY1, forward 5′-GAAACTTGAGTTCGGCTC 
TAGG-3′ and reverse 5′-GCTTAGCAGATCCTTGCT 
CCAT-3′; and CD133, forward 5′- ACCAACACCAAGAA 
CAAGGC-3′ and reverse 5′-GGAGCTGACTTGAATT 
GAGG-3′. Real-time RT-PCR was performed using SYBR 
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Green Master Mix (TOYOBO) with an ABI instrument 
(Applied Biosystems Inc.). The normalization control was 
B-actin.
Western blot analysis and immunoprecipitation
Cell lysate extractions were prepared with RIPA 
buffer 1 % NP-40; 0.1% sodium dodecyl sulfate; 0.5% 
deoxycholate; 150 mM NaCl; 50 mM Tris, pH 7.5) 
and a protease inhibiter cocktail. 10–20 μg total protein 
of each lysate was resolved in SDS PAGE gels and 
electrotransferred to PVDF membranes, and then blocked 
in 5% skim milk in 0.05% Tween-20 with 1× PBS 
(PBST). Primary antibodies were incubated with the 
blots at a 1:1000 dilution in minimal volumes of 5% BSA 
(Bovine serum albumin) in PBST buffer for 1 hr at room 
temperature or over-night at 4°C. Anti-mouse or anti-
rabbit goat-HRP-conjugated secondary antibodies were 
incubated at a 1:3000 dilution in 5% BSA in PBST buffer 
for 1 hr at room temperature. Antibodies used in this study 
were anti-galectin-3, anti-GAPDH, anti-Lamin A/C, anti-
Notch1, anti-ZEB1, anti-SNAIL, anti-TWIST, anti-Nanog, 
anti-Sox2, and anti-Oct4 that were purchased from Santa 
Cruz Biotechnology. Anti-activated Notch1 (NICD1) was 
obtained from Abcam. Anti-c-MYC and anti-HES1 were 
purchased from Cell Signaling. Membranes that were 
probed with primary antibodies and secondary antibodies 
were detected by ECL solution (Amersham Life Science) 
using a LAS-3000 (Fujifilm) detector, according to the 
manufacturer’s directions. Immunoprecipitation was 
carried out using A/G agarose beads coated with anti-
galectin-3 (Santa Cruz Biotechnology), anti-FLAG 
(Sigma) and anti-activated Notch1 (Cambridge, MA, 
USA). The proteins were detected by western blot analysis 
using antibodies against anti-galectin-3, anti-activated 
Notch1, and anti-Notch1. Mouse/rabbit IgG (Santa Cruz 
Biotechnology) was used as a negative control [38].
Fractionation of cellular extracts
Nuclear and cytoplasmic extracts were prepared 
from SKOV3 and A2780 cells after treatment with 
galectin-3 siRNA and transfection with galectin-3 
overexpression vectors. Cells were lysed in Buffer A 
(10 mM HEPES (pH 7.9), 1.5 mM Mgcl2, 10 mM KCl, 1 
mM DTT, 0.2 mM PMSF, 0.1% NP-40) containing a Xpert 
protease inhibitor cocktail (GenDEPOT, Barker, TX, USA) 
and phosphatase inhibitor (NaF, Na3VO4), incubation 
on ice for 15 min. The cell lysate was centrifuged for 
10 min at 850 G at 4°C and discard the supernatant. 
Next, resuspend the pellet with Buffer C (20 mM HEPES 
(pH 7.9), 25 % Glycerol, 0.42 M Nacl, 0.2 mM EDTA, 
1.5 mM Mgcl2, 1 mM DTT, 0.2 mM PMSF) and vortex 
for 15 sec. Incubate the cell lysate for 30 min on ice and 
vortex every 10 min for 15 sec. After incubation the 
cell lysate were centrifuged for 10 min at 13,200 rpm at 
4°C and collect the supernatant (Nuclear). Western blot 
analysis was performed as described previously [39] with 
nuclear fraction protein samples.
Apoptosis detection assays
SKOV3 and A2780 cells were plated onto culture 
plates. Next day, cells were transfected with Galectin-3 
siRNA or Galectin-3 expression vector. After 6 hrs, media 
is changed. And then treat with paclitaxel (5 μM) for 48 hrs. 
After the time passed, cells were harvested. Cells were 
washed twice with cold PBS and then resuspended in 1× 
Annexin V Binding at a concentration of 1 × 106 cells/ml. 
Then, 100 μl of the solution (1 × 105 cells) was transferred 
to a 1 ml culture tube and 5 μl of PE Annexin V and 5 μl 
7-AAD each sample. The cells were gently vortexed and 
incubated for 15 min at RT in the dark. We added 400 μl 
of 1× Annexin Binding Buffer to each tube and transferred 
the solution to FACS filter tubes. Apoptosis distribution 
was measured by Annexin V staining using FACS LSRII.
Cell viability analysis
Stable cells were plated in 96-well culture plates 
(5,000 cells/well). After 48 hrs, highly sensitive water-
soluble tetrazolium salt (WST) solution (Daeil, Seoul, 
Korea) was subsequently added to each well. WST 
solution works through the cleavage of tetrazolium salt 
into a water-soluble formazan by the succinate-tetrazolium 
reductase system of the mitochondrial respiratory chain. 
It is active only in viable cells. After 1 hr of additional 
incubation, the plate was shaken gently. The absorbance 
was measured using an ELISA reader at a wavelength 
of 450 nm. Inhibition of cell proliferation by drugs 
(paclitaxel, cisplatin) was measured using the WST assay. 
Immunocytochemistry and 
immunohistochemistry
Immunocytochemistry was performed as described 
previously [9]. Briefly, cells in chamber slides were 
fixed with 4% formaldehyde at 4°C for 30 min, washed 
with PBS, and permeabilized in 0.5% Triton X-100 for 
10 min. Cells were incubated with primary antibodies 
(galectin-3 and NICD) at 4°C and then were incubated 
with fluorescein isothiocyanate anti-mouse and Cy5 anti-
rabbit secondary antibodies (Invitrogen), as well as with 
4,6-diamino-2-phenylindole staining solution. Images were 
analyzed by confocal microscopy (LSM 700, Carl Zeiss). 
Immunohistochemistry for galectin-3, NICD, Sox-2, 
Oct-4, and Nanog of xenograft mouse tumor tissues was 
performed according to instructions, using a Vectastain 
ABC kit and DAB substrate kit (Vector Laboratories, 
Burlingame, CA).
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Animal experiments
All animal experiments were approved by the 
Institutional Review Board of the Yonsei University 
College of Medicine and were performed in specific 
pathogen-free facilities in accordance with the University’s 
Guidelines for the Care and Use of Laboratory Animals 
(2014–0027). The preparation of xenografted mice was 
performed as described previously [40].
Statistical analysis
Two tumors per mouse were obtained and the mean 
tumor volume per mouse was analyzed. Unpaired t-tests 
were used to analyze the mean tumor volume in xenografted 
mice. All statistical tests are two sided, and the values are 
expressed as the mean with 95% confidence intervals (CI). 
P-value < 0.05 was considered statistically significant. 
Statistical analyses were performed using GraphPad Prism 
(version 6; GraphPad Software Inc., La Jolla, CA, USA). 
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